Omar Nadeem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Omar Nadeem has a total of 513 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Sperling
Dana-Farber Cancer Institute, Boston, MA
38 shared publications - Shonali Midha
Dana-Farber Cancer Institute, Boston, USA
37 shared publications - Jack Khouri
Cleveland Clinic, Cleveland, USA
35 shared publications - Larry D. Anderson
University of Texas Southwestern Medical Center, Dallas, Texas, United States
35 shared publications - Aimaz Afrough
UT Southwestern Medical Center, Dallas, TX
34 shared publications - Andrew Jay Portuguese
Fred Hutchinson Cancer Center, Seattle, WA
34 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
- 2 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Open AccessDenosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
- Open Access
- 22 October 2026
- Published by Springer Nature in Blood Cancer Journal
Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care
- 22 October 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessEarly treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- Open Access
- 11 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3812-3822
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
Teclistamab, a B cell maturation antigen-targeting bispecific antibody, has demonstrated substantial activity in relapsed multiple myeloma (MM), particularly in earlier lines of therapy, and may have higher efficacy in high-risk smoldering MM (HR-SMM) with a more functional immune system. In the randomized phase 2 ImmunoPRISM trial, we compared fixed-duration teclistamab with lenalidomide–dexamethasone (Rd) in HR-SMM. After a six-patient safety run-in, patients were randomized 2:1 to teclistamab or Rd. The primary endpoint was complete response (CR) rate. As of 26 May 2026, 59 patients were treated—45 received teclistamab and 14 received Rd. Teclistamab treatment induced a CR in 77.8% patients versus 0% with Rd, and minimal residual disease negativity at 10−5 in 82.2% patients. At a median follow-up of 24.5 months, 2-year progression-free survival was 92% with teclistamab versus 49% with Rd. Overall, response rates, duration of response and time to progression (TTP) were significantly improved in teclistamab compared to Rd. Toxicities in the teclistamab arm included grades 1–2 cytokine release syndrome, no neurotoxicity and no increase in grade 3 infections compared to Rd (20% versus 21%). No deaths occurred in either arm. Teclistamab represents a highly active immune-interception strategy for HR-SMM. ClinicalTrials.gov registration: NCT05469893.
- 11 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3812-3822
Open AccessTeclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
Teclistamab, a B cell maturation antigen-targeting bispecific antibody, has demonstrated substantial activity in relapsed multiple myeloma (MM), particularly in earlier lines of therapy, and may have higher efficacy in high-risk smoldering MM (HR-SMM) with a more functional immune system. In the randomized phase 2 ImmunoPRISM trial, we compared fixed-duration teclistamab with lenalidomide–dexamethasone (Rd) in HR-SMM. After a six-patient safety run-in, patients were randomized 2:1 to teclistamab or Rd. The primary endpoint was complete response (CR) rate. As of 26 May 2026, 59 patients were treated—45 received teclistamab and 14 received Rd. Teclistamab treatment induced a CR in 77.8% patients versus 0% with Rd, and minimal residual disease negativity at 10−5 in 82.2% patients. At a median follow-up of 24.5 months, 2-year progression-free survival was 92% with teclistamab versus 49% with Rd. Overall, response rates, duration of response and time to progression (TTP) were significantly improved in teclistamab compared to Rd. Toxicities in the teclistamab arm included grades 1–2 cytokine release syndrome, no neurotoxicity and no increase in grade 3 infections compared to Rd (20% versus 21%). No deaths occurred in either arm. Teclistamab represents a highly active immune-interception strategy for HR-SMM. ClinicalTrials.gov registration: NCT05469893.
- 3 September 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2622-2626
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma
- 3 September 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2622-2626
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma
- Open Access
- 27 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
- 27 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessImpact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
- Top Cited PapersOpen Access
- 2 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1240-1250
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel, BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). This phase 1, dose-escalation/expansion study (NCT04674813) enrolled adult patients with RRMM and ≥3 prior antimyeloma treatment regimens, including an immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody. At baseline, patients (N=84) had a median of 5 prior regimens and 49% had previously received BCMA-targeted therapy, of whom 38% received CAR T-cell therapy. Arlo-cel was administered as a one-time intravenous infusion of 25×106-450×106 CAR T cells. Primary endpoints were safety and maximum tolerated dose (MTD); secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Data cutoff was 23August2024. Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell-associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1/2 and frequency appeared dose-dependent. One death occurred from CRS at highest dose level. On-target/off-tumor skin (30%), nail (19%), and oral (32%) adverse events were transient, grade 1/2; most resolved without intervention. MTD was not reached. With median follow-up of 16.1 months, ORR=87% (complete response rate=53%), median duration of response=18.0 months, and median PFS=18.3 months (95% CI, 11.8-21.9) (n=79). The 1-year OS rate was 90% (N=84). In conclusion, arlo-cel had a safety profile supportive of future study and demonstrated deep and durable responses, with promising PFS and OS in patients with heavily pretreated RRMM.
- 2 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1240-1250
Top Cited PapersOpen AccessArlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel, BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). This phase 1, dose-escalation/expansion study (NCT04674813) enrolled adult patients with RRMM and ≥3 prior antimyeloma treatment regimens, including an immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody. At baseline, patients (N=84) had a median of 5 prior regimens and 49% had previously received BCMA-targeted therapy, of whom 38% received CAR T-cell therapy. Arlo-cel was administered as a one-time intravenous infusion of 25×106-450×106 CAR T cells. Primary endpoints were safety and maximum tolerated dose (MTD); secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Data cutoff was 23August2024. Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell-associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1/2 and frequency appeared dose-dependent. One death occurred from CRS at highest dose level. On-target/off-tumor skin (30%), nail (19%), and oral (32%) adverse events were transient, grade 1/2; most resolved without intervention. MTD was not reached. With median follow-up of 16.1 months, ORR=87% (complete response rate=53%), median duration of response=18.0 months, and median PFS=18.3 months (95% CI, 11.8-21.9) (n=79). The 1-year OS rate was 90% (N=84). In conclusion, arlo-cel had a safety profile supportive of future study and demonstrated deep and durable responses, with promising PFS and OS in patients with heavily pretreated RRMM.
- Open Access
- 28 May 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma
Triplets incorporating proteasome inhibitors, immunomodulatory drugs, and dexamethasone are active regimens for patients with relapsed/refractory multiple myeloma (RRMM). All-oral regimens may offer greater real-world feasibility and convenience than other options. This phase I/II dose-escalation and expansion study evaluated the oral proteasome inhibitor ixazomib at a dose of 3 or 4 mg on a twice-weekly schedule (days 1, 4, 8, and 11) in 21-day cycles, plus pomalidomide at a dose of 2, 3, or 4 mg (days 1–14) and dexamethasone 12 or 8 mg (days of/after ixazomib), in 50 patients with RRMM. Patients had received a median of 2 prior lines, with 98.0% and 88.0% having received prior lenalidomide and bortezomib, respectively. The highest dose level investigated (ixazomib 4 mg, pomalidomide 4 mg) was the recommended phase II dose (RP2D). Patients received a median of 11 cycles. Common toxicities were neutropenia (76.0%; grade 3/4 22.0%/4.0%), thrombocytopenia (70.0%; 8.0%/8.0%), leukopenia (68.0%; 22.0%/0%), fatigue (52.0%; 4.0%/0%), and anemia (46.0%; 2.0%/0%). During dose escalation, two dose-limiting toxicities (grade 3 upper respiratory tract infection; grade 3 neutropenia) were reported. The overall response rate was 60.0% (24.0% ≥very good partial response [VGPR]) in all 50 patients and 65.8% (28.9% ≥VGPR) in the 38 patients who received the RP2D; the median duration of response was 18.0 and 19.3 months, median progression-free survival was 13.9 and 17.8 months, and 3-year overall survival rates were 85.2% and 80.3%, respectively. Twice-weekly ixazomib plus pomalidomide-dexamethasone is a well-tolerated, efficacious all-oral regimen with real-world utility in RRMM.
- 28 May 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessA phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma
Triplets incorporating proteasome inhibitors, immunomodulatory drugs, and dexamethasone are active regimens for patients with relapsed/refractory multiple myeloma (RRMM). All-oral regimens may offer greater real-world feasibility and convenience than other options. This phase I/II dose-escalation and expansion study evaluated the oral proteasome inhibitor ixazomib at a dose of 3 or 4 mg on a twice-weekly schedule (days 1, 4, 8, and 11) in 21-day cycles, plus pomalidomide at a dose of 2, 3, or 4 mg (days 1–14) and dexamethasone 12 or 8 mg (days of/after ixazomib), in 50 patients with RRMM. Patients had received a median of 2 prior lines, with 98.0% and 88.0% having received prior lenalidomide and bortezomib, respectively. The highest dose level investigated (ixazomib 4 mg, pomalidomide 4 mg) was the recommended phase II dose (RP2D). Patients received a median of 11 cycles. Common toxicities were neutropenia (76.0%; grade 3/4 22.0%/4.0%), thrombocytopenia (70.0%; 8.0%/8.0%), leukopenia (68.0%; 22.0%/0%), fatigue (52.0%; 4.0%/0%), and anemia (46.0%; 2.0%/0%). During dose escalation, two dose-limiting toxicities (grade 3 upper respiratory tract infection; grade 3 neutropenia) were reported. The overall response rate was 60.0% (24.0% ≥very good partial response [VGPR]) in all 50 patients and 65.8% (28.9% ≥VGPR) in the 38 patients who received the RP2D; the median duration of response was 18.0 and 19.3 months, median progression-free survival was 13.9 and 17.8 months, and 3-year overall survival rates were 85.2% and 80.3%, respectively. Twice-weekly ixazomib plus pomalidomide-dexamethasone is a well-tolerated, efficacious all-oral regimen with real-world utility in RRMM.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (11) , 2470-2482
eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies
Key Points: eGFR discordance was associated with higher risk of AKI in allogeneic hematopoietic stem cell transplantation and adoptive T-cell therapies. Among hematopoietic stem cell transplantation recipients, eGFR discordance was associated with slower time-to-platelet engraftment. Among adoptive T-cell recipients, eGFR discordance was associated with prolonged cytopenia. Background: Discordance between eGFR on the basis of serum creatinine (eGFR cr ) versus cystatin C (eGFR cys ) is associated with adverse outcomes in patients with and without cancer. We hypothesized that eGFR discordance is associated with AKI and death after hematopoietic stem cell transplantation (HSCT) or receipt of adoptive T-cell therapies. Methods: We conducted a multicenter study of adults receiving allogeneic HSCT and adoptive T-cell therapies who had paired serum creatinine and cystatin C values obtained in the 30 days preceding conditioning or lymphodepleting chemotherapy. The primary exposure was eGFR discordance, defined as eGFR cys ≥30% lower than eGFR cr . The primary outcome was a composite outcome of AKI (≥50% increase in serum creatinine or receipt of KRT) or death within 90 days after HSCT or adoptive T-cell infusion. Secondary outcomes included time-to-platelet engraftment in HSCT and prolonged cytopenia in adoptive T-cell recipients. We used multivariable logistic regression and cause-specific Cox regression with inverse probability weighting to adjust for confounders. Results: Of 274 patients receiving HSCT (median age, 65 years; interquartile range, 52–71; 43% female), 86 (31%) had an eGFR discordance. Among 236 adoptive T-cell recipients (median age, 67 years; interquartile range, 60–74; 59% female), 78 (33%) had a discordance in eGFR. eGFR discordance was associated with higher odds of AKI or death in HSCT (odds ratio, 1.75; 95% confidence interval, 1.03 to 3.02) and adoptive T-cell recipients (odds ratio, 2.37; 95% confidence interval, 1.12 to 4.94). However, adjustment for eGFR cr-cys attenuated these associations in both cohorts. eGFR discordance was also associated with slower time-to-platelet engraftment in HSCT recipients and prolonged cytopenia after adoptive T-cell therapy. Conclusions: A pretreatment eGFR discordance was associated with AKI or death in HSCT and adoptive T-cell recipients; however, this association was attenuated after adjusting for eGFR cr-cys .
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (11) , 2470-2482
eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies
Key Points: eGFR discordance was associated with higher risk of AKI in allogeneic hematopoietic stem cell transplantation and adoptive T-cell therapies. Among hematopoietic stem cell transplantation recipients, eGFR discordance was associated with slower time-to-platelet engraftment. Among adoptive T-cell recipients, eGFR discordance was associated with prolonged cytopenia. Background: Discordance between eGFR on the basis of serum creatinine (eGFR cr ) versus cystatin C (eGFR cys ) is associated with adverse outcomes in patients with and without cancer. We hypothesized that eGFR discordance is associated with AKI and death after hematopoietic stem cell transplantation (HSCT) or receipt of adoptive T-cell therapies. Methods: We conducted a multicenter study of adults receiving allogeneic HSCT and adoptive T-cell therapies who had paired serum creatinine and cystatin C values obtained in the 30 days preceding conditioning or lymphodepleting chemotherapy. The primary exposure was eGFR discordance, defined as eGFR cys ≥30% lower than eGFR cr . The primary outcome was a composite outcome of AKI (≥50% increase in serum creatinine or receipt of KRT) or death within 90 days after HSCT or adoptive T-cell infusion. Secondary outcomes included time-to-platelet engraftment in HSCT and prolonged cytopenia in adoptive T-cell recipients. We used multivariable logistic regression and cause-specific Cox regression with inverse probability weighting to adjust for confounders. Results: Of 274 patients receiving HSCT (median age, 65 years; interquartile range, 52–71; 43% female), 86 (31%) had an eGFR discordance. Among 236 adoptive T-cell recipients (median age, 67 years; interquartile range, 60–74; 59% female), 78 (33%) had a discordance in eGFR. eGFR discordance was associated with higher odds of AKI or death in HSCT (odds ratio, 1.75; 95% confidence interval, 1.03 to 3.02) and adoptive T-cell recipients (odds ratio, 2.37; 95% confidence interval, 1.12 to 4.94). However, adjustment for eGFR cr-cys attenuated these associations in both cohorts. eGFR discordance was also associated with slower time-to-platelet engraftment in HSCT recipients and prolonged cytopenia after adoptive T-cell therapy. Conclusions: A pretreatment eGFR discordance was associated with AKI or death in HSCT and adoptive T-cell recipients; however, this association was attenuated after adjusting for eGFR cr-cys .
- Top Cited PapersOpen Access
- 20 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 1-10
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtagene autoleucel (cilta-cel) at 0.3–0.5 × 106 or >0.5 × 106 viable CAR+ T cells per kilogram without induction or bridging therapy. Patients with >40% marrow involvement were excluded. Primary endpoints were dose-limiting toxicities (DLTs) and treatment-emergent adverse events; secondary endpoints included response and minimal residual disease (MRD) negativity. As of 11 February 2026, 20 patients had been treated. The trial met the prespecified endpoints. No DLTs occurred. Adverse events included transient cytopenias (90% grade 3/4) and cytokine release syndrome (100% grade 1/2). Non-immune effector cell-associated neurotoxicity syndrome neurologic toxicities (NINTs) occurred in seven patients, with four comprising cranial nerve palsies that completely resolved. Three patients had persistent grade 1 symptoms. At a median follow-up of 15.3 months, all patients achieved MRD negativity 10−6 by 2 months and have remained MRD negative. Sixteen patients with follow-up >6 months achieved a complete response; no progression or deaths were observed. Cilta-cel produced rapid, deep, sustained MRD-negative responses in HR-SMM without induction therapy. Toxicities were consistent with the safety profile of cilta-cel. ClinicalTrials.gov: NCT05767359.
- 20 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 1-10
Top Cited PapersOpen AccessCiltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtagene autoleucel (cilta-cel) at 0.3–0.5 × 106 or >0.5 × 106 viable CAR+ T cells per kilogram without induction or bridging therapy. Patients with >40% marrow involvement were excluded. Primary endpoints were dose-limiting toxicities (DLTs) and treatment-emergent adverse events; secondary endpoints included response and minimal residual disease (MRD) negativity. As of 11 February 2026, 20 patients had been treated. The trial met the prespecified endpoints. No DLTs occurred. Adverse events included transient cytopenias (90% grade 3/4) and cytokine release syndrome (100% grade 1/2). Non-immune effector cell-associated neurotoxicity syndrome neurologic toxicities (NINTs) occurred in seven patients, with four comprising cranial nerve palsies that completely resolved. Three patients had persistent grade 1 symptoms. At a median follow-up of 15.3 months, all patients achieved MRD negativity 10−6 by 2 months and have remained MRD negative. Sixteen patients with follow-up >6 months achieved a complete response; no progression or deaths were observed. Cilta-cel produced rapid, deep, sustained MRD-negative responses in HR-SMM without induction therapy. Toxicities were consistent with the safety profile of cilta-cel. ClinicalTrials.gov: NCT05767359.